1. Home
  2. NTLA vs SLDP Comparison

NTLA vs SLDP Comparison

Compare NTLA & SLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$10.75

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$5.29

Market Cap

876.8M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTLA
SLDP
Founded
2014
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Electrical Products
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
986.9M
876.8M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
NTLA
SLDP
Price
$10.75
$5.29
Analyst Decision
Buy
Strong Buy
Analyst Count
22
1
Target Price
$19.83
$7.00
AVG Volume (30 Days)
3.6M
5.8M
Earning Date
02-26-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$57,528,000.00
$19,802,000.00
Revenue This Year
$1.96
$27.38
Revenue Next Year
N/A
$36.18
P/E Ratio
N/A
N/A
Revenue Growth
33.52
9.85
52 Week Low
$5.90
$0.68
52 Week High
$28.25
$8.86

Technical Indicators

Market Signals
Indicator
NTLA
SLDP
Relative Strength Index (RSI) 61.75 57.76
Support Level $8.94 $4.82
Resistance Level $9.62 $5.47
Average True Range (ATR) 0.46 0.27
MACD 0.28 0.13
Stochastic Oscillator 89.42 87.92

Price Performance

Historical Comparison
NTLA
SLDP

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About SLDP Solid Power Inc.

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

Share on Social Networks: